Funding

Horizon 2020 Programme

AbilityPharma: Accelerating Solutions for Pancreatic Cancer

(PanC-ASAP)


The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 954825.
 

Horizon 2020 Framework Programme
Call: H2020-EIC-SMEInst-2018-2020-3
Project: 954825 — PanC-ASAP
 
PanC-ASAP is a project that aims to develop ABTL0812, a first-in-class autophagy inducer drug, for the treatment of metastatic pancreatic cancer by performing a phase 2 multicenter double-blind placebo-controlled clinical trial to investigate ABTL0812 in combination with the chemotherapy combo FOLFIRINOX.
 
The Problem:

Pancreatic cancer, sometimes referred as the ‘’neglected cancer’’, is the seventh leading cause of cancer-related deaths worldwide and third in EU.
The high mortality rates of pancreatic cancer are due to lack of appropriate diagnosis, treatment and cataloging of cancer cases.
Due to its high lethality, it is an orphan disease with an urgent unmet clinical need for new efficacious and safe therapies.
 
 


















The solution:

ABTL0812 is a first-in-class fully differentiated oral targeted anticancer compound that induces autophagy-mediated cytotoxicity selectively in cancer cells.

In preclinical in vitro and animal pancreatic cancer models, ABTL0812 showed efficacy as a single agent and in combination with current standard-of-care treatments without additional toxicity. These results granted an Orphan Drug Designation (ODD) to ABTL0812 for pancreatic cancer treatment from the EMA and the FDA.

Moreover, ABTL0812 is a clinical stage drug. A first-in-human phase 1/1b clinical trial demonstrated that ABTL0812 oral treatment is safe and well tolerated. Subsequently, a phase 1/2 showed the superiority of combining ABTL0812 with standard of care chemotherapy over chemotherapy alone in endometrial and lung cancer.
 
 

 

ABTL0812 mechanism of action and synergy with chemotherapy. A) ABTL0812 has a dual anticancer action: 1) ER stress activation and 2) Akt-mTOR blockade. Both actions converge in the induction of a robust cytotoxic autophagy that leads to cancer cell death B) The main chemotherapy mechanism resistance is the activation of Akt/mTOR that prevents cancer cell death; ABTL0812 avoids the activation of Akt/mTOR and thus potentiates the efficacy of chemotherapy.


Overall strategy:

AbilityPharma will perform a phase 2 clinical trial in pancreatic cancer to investigate the safety and efficacy ABTL0812 in combination with the standard-of-care chemotherapy FOLFIRINOX.

This proof of concept study has the potential to lead to a further development of the treatment and/or its early conditional approval and, therefore, address this urgent unmet medical by making the treatment available to pancreatic cancer patients.
 

News about the project: 

March 25, 2020 - AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer
 

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG